يعرض 1 - 10 نتائج من 69 نتيجة بحث عن '"Uwe M. Martens"', وقت الاستعلام: 0.74s تنقيح النتائج
  1. 1
    Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial

    المؤلفون: Uwe M. Martens, Jun Ho Jang, Farhad Ravandi, Julia Braverman, Shien Guo, Ming Chung Wang, Jane L. Liesveld, C.L. Beach, Teresa Bernal, Barry S. Skikne, Christopher Pocock, Jiří Mayer, Peiwen Yu, Hartmut Döhner, Gail J. Roboz, Qian Dong, Ling Shi, Dominik Selleslag, Andrew H. Wei, Salem Abi Nehme, Ignazia La Torre, Hervé Dombret

    المصدر: Haematologica. 106:3240-3244

    مصطلحات موضوعية: Oncology, Health related quality of life, medicine.medical_specialty, business.industry, Internal medicine, medicine, MEDLINE, Myeloid leukemia, Hematology, Placebo, business, Oral Azacitidine

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::cc56742deef2ae04ca2a891cfa3f2060Test
    https://doi.org/10.3324/haematol.2021.279174Test


    أضف إلى المفضلة
  2. 2
    Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

    المؤلفون: Uwe M. Martens, Lionel Larribère

    المصدر: Cancers
    Cancers, Vol 13, Iss 5698, p 5698 (2021)

    مصطلحات موضوعية: Oncology, Cancer Research, Treatment response, medicine.medical_specialty, liquid biopsy, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Context (language use), adjuvant therapy, Review, ctDNA, Minimal residual disease, Advanced cancer, Clinical trial, Internal medicine, Adjuvant therapy, minimal residual disease, Medicine, Treatment resistance, Liquid biopsy, business, RC254-282

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f8b918f9b74ed55923427f49b832b13Test
    http://europepmc.org/articles/PMC8616165Test


    أضف إلى المفضلة
  3. 3
    Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)

    المؤلفون: Thomas J. Ettrich, Jens Atzpodien, Stephan Kanzler, Swen Wessendorf, Swantje Held, Petra Buechner-Steudel, Axel Florschütz, D Nörenberg, Max Seidensticker, Anke Reinacher-Schick, Jorge Riera-Knorrenschild, Dominik Paul Modest, Michael Geissler, J. Greeve, Uwe M. Martens, Volker Heinemann, Sebastian Stintzing, Andrea Tannapfel, Annika Kurreck, Thomas Seufferlein

    المصدر: Journal of Cancer Research and Clinical Oncology

    مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Organoplatinum Compounds, Colorectal cancer, Original Article – Clinical Oncology, Leucovorin, Disease, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Disease dynamics, FOLFOXIRI, Metastatic colorectal cancer, Panitumumab, General Medicine, Middle Aged, Primary tumor, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Female, Fluorouracil, Colorectal Neoplasms, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Randomization, BRAF, Combination chemotherapy, 03 medical and health sciences, Internal medicine, medicine, Humans, Aged, business.industry, Wild type, medicine.disease, Early tumor shrinkage, 030104 developmental biology, Tumor progression, Mutation, Primary tumor site, ras Proteins, Camptothecin, business, Depth of response

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6834639b3ec002c9bc256673519e750Test
    https://doi.org/10.1007/s00432-020-03257-zTest


    أضف إلى المفضلة
  4. 4
    Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

    المؤلفون: Thomas Schroeder, Hartmut Döhner, Heinz A. Horst, Arnold Ganser, Nadezda Basara, Julia Krzykalla, Karin Mayer, Axel Benner, Uwe M. Martens, Martin Bentz, Michael Lübbert, Peter Paschka, Thomas Kindler, Richard F. Schlenk, Michael Girschikofsky, Michael Heuser, Gerald Wulf, Elisabeth Koller, Katharina Götze, Richard Greil, Bernd Hertenstein, Felicitas Thol, Jürgen Krauter, Daniela Weber, David Nachbaur, Claudia Leis, Jan Schleicher, Walter Fiedler, Maisun Abu Samra, Konstanze Döhner, Silke Kapp-Schwoerer, Mohammed Wattad, Verena I. Gaidzik

    المصدر: Journal of Clinical Oncology

    مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, NPM1, Adolescent, Gemtuzumab ozogamicin, CD33, Tretinoin, Young Adult, Antineoplastic Agents, Immunological, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Hematologic Malignancy, Humans, Medicine, Prospective Studies, Aged, Etoposide, Aged, 80 and over, business.industry, Cytarabine, Nuclear Proteins, Myeloid leukemia, ORIGINAL REPORTS, Induction Chemotherapy, Middle Aged, Gemtuzumab, Progression-Free Survival, ddc, Consolidation Chemotherapy, Leukemia, Myeloid, Acute, Early results, Mutation, Female, Idarubicin, business, Nucleophosmin, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59fa1b4692c7405ce74baee118fdeeecTest
    https://doi.org/10.1200/jco.19.01406Test


    أضف إلى المفضلة
  5. 5
    Magnitude of the Age-Advancement Effect of Comorbidities in Colorectal Cancer Prognosis

    المؤلفون: Uwe M. Martens, Michael Hoffmeister, Viola Walter, Jenny Chang-Claude, Lina Jansen, Hermann Brenner, Daniel Boakye

    المصدر: Journal of the National Comprehensive Cancer Network. 18:59-68

    مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Colorectal cancer, Population, Comorbidity, Risk Assessment, Disease-Free Survival, Germany, Internal medicine, medicine, Humans, Mass Screening, education, Survival rate, Aged, Neoplasm Staging, Aged, 80 and over, education.field_of_study, business.industry, Proportional hazards model, Hazard ratio, Age Factors, Case-control study, Chemoradiotherapy, Adjuvant, Colonoscopy, Middle Aged, Nomogram, Prognosis, medicine.disease, Survival Rate, Oncology, Chemotherapy, Adjuvant, Case-Control Studies, Female, Neoplasm Recurrence, Local, Colorectal Neoplasms, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e18b9fc27681151ecbc2ee268019b8d7Test
    https://doi.org/10.6004/jnccn.2019.7346Test


    أضف إلى المفضلة
  6. 6
    FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

    المؤلفون: Uwe M. Martens, Swen Wessendorf, Heinemann, Petra Buechner-Steudel, J. Greeve, Axel Florschütz, Thomas J. Ettrich, Andrea Tannapfel, Anke Reinacher-Schick, Thomas Seufferlein, Michael Geissler, Swantje Held, Jens Atzpodien, Jens Ricke, Max Seidensticker, Jorge Riera-Knorrenschild, Stephan Kanzler, Dominik Paul Modest, Dominik Nörenberg

    المصدر: Journal of Clinical Oncology. 37:3401-3411

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, FOLFOXIRI, business.industry, Colorectal cancer, Wild type, medicine.disease, Oxaliplatin, Irinotecan, 03 medical and health sciences, Folinic acid, 0302 clinical medicine, Fluorouracil, 030220 oncology & carcinogenesis, Internal medicine, medicine, Panitumumab, 030211 gastroenterology & hepatology, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b2c87cf9f825e3641aa69916765fb581Test
    https://doi.org/10.1200/jco.19.01340Test


    أضف إلى المفضلة
  7. 7
    Treatment selection bias for chemotherapy persists in colorectal cancer patient cohort studies even in comprehensive propensity score analyses

    المؤلفون: Uwe M. Martens, Daniel Boakye, Lina Jansen, Hermann Brenner, Viola Walter, Jenny Chang-Claude, Michael Hoffmeister

    المصدر: Clinical Epidemiology. 11:821-832

    مصطلحات موضوعية: medicine.medical_specialty, education.field_of_study, Epidemiology, business.industry, Colorectal cancer, Proportional hazards model, Confounding, Population, Hazard ratio, 030204 cardiovascular system & hematology, medicine.disease, Comorbidity, Confidence interval, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Propensity score matching, medicine, 030212 general & internal medicine, business, education

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::75d2ebe7cae97495ea52b8326b87ad7bTest
    https://doi.org/10.2147/clep.s215983Test


    أضف إلى المفضلة
  8. 8
    Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

    المؤلفون: Lazar Vujanovic, Jun Li, Anthony Gonçalves, Julie E. Stein, Chrisann Kyi, Rom Leidner, Christine H. Chung, Hélène Gauthier, Janis M. Taube, Uwe M Martens, Tian Chen, Robert L. Ferris, William H. Sharfman, Bin Li, Simon I. Chiosea, Lot A. Devriese, William C. Spanos, Suzanne L. Topalian, Adam Barrows

    المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Immunology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Biopsy, Clinical endpoint, Immunology and Allergy, Medicine, Stage (cooking), Adverse effect, RC254-282, Pharmacology, medicine.diagnostic_test, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunotherapy, 030104 developmental biology, Tolerability, Tumor progression, 030220 oncology & carcinogenesis, Molecular Medicine, Nivolumab, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07a9f0d3402b33758610051fccbc0a24Test
    https://jitc.bmj.com/content/9/6/e002568.fullTest


    أضف إلى المفضلة
  9. 9
    Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

    المؤلفون: Matthias Egger, Stephan Probst, Jörg Trojan, Alexander Reichart, Dirk M Behringer, Salah-Eddin Al-Batran, Volker Rethwisch, Michael Pohl, Gerald Illerhaus, Jan Stoehlmacher, Jörg Weniger, Daniel Pink, Wael Hozaeel, Rolf Mahlberg, Georg Martin Haag, Severin Daum, Carmen Löhr, Wolff Schmiegel, Michael Heike, G. Schuch, Timo Gaiser, Flot Aio Investigators, Thorsten Oliver Goetze, Helga Bernhard, Sebastian Belle, Nils Homann, Johannes Meiler, Hans-Georg Kopp, Nicole Prasnikar, Christian Teschendorf, Andreas Block, Michael Schenk, Volker Heinemann, Markus Moehler, Stefan Kasper, Claudia Pauligk, Kim Barbara Luley, Ralf Hofheinz, Harald Schmalenberg, Michael Kneba, Frank Kullmann, Wolf O. Bechstein, Jörg T. Hartmann, Uwe M. Martens, Martin Schuler, U. Lindig, Fuat Oduncu, Peter C. Thuss-Patience, Thomas Kraus, Gunnar Folprecht, Frank Mayer, Michael Koenigsmann, Elke Jäger, Wolfgang Fischbach, Stefan Mönig, Ludwig Fischer von Weikersthal, Martina Güntner, Karsten Schulmann

    المصدر: The Lancet. 393:1948-1957

    مصطلحات موضوعية: medicine.medical_specialty, education.field_of_study, Chemotherapy, business.industry, medicine.medical_treatment, Population, Medizin, General Medicine, Perioperative, 030204 cardiovascular system & hematology, Gastroenterology, Oxaliplatin, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Docetaxel, Fluorouracil, Internal medicine, Medicine, 030212 general & internal medicine, business, education, medicine.drug, Epirubicin

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb9328f246b91519e1997e982c1bc7cTest
    https://doi.org/10.1016/s0140-6736Test(18)32557-1


    أضف إلى المفضلة
  10. 10
    Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

    المؤلفون: Uwe M. Martens, Jörg Westermann, Peter Paschka, Helmut R. Salih, Richard Greil, Thomas Südhoff, Konstanze Döhner, Julia Krzykalla, Thomas Kindler, Bernd Hertenstein, Verena I. Gaidzik, Wolfgang Herr, Michael Girschikofsky, Alexander Burchardt, Thomas Schroeder, Gerhard Held, Michael Heuser, Katharina Götze, Gerald Wulf, Roland Schroers, Daniela Weber, Richard F. Schlenk, Elisabeth Lange, Doris Kraemer, Hartmut Döhner, Axel Benner, Michael Lübbert, Mark Ringhoffer, Arnold Ganser, Felicitas Thol, Hans-Günter Derigs, Martin Grießhammer, Heinz-August Horst, Lore Marretta, Jürgen Krauter, Walter Fiedler, Hans Salwender, Dominik Wolf

    المصدر: Blood. 133:840-851

    مصطلحات موضوعية: medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunology, Hazard ratio, Cell Biology, Hematology, Hematopoietic stem cell transplantation, Biochemistry, Chemotherapy regimen, Transplantation, chemistry.chemical_compound, chemistry, Maintenance therapy, Internal medicine, medicine, Cytarabine, Midostaurin, business, Survival rate, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::977428423939e297a74c72e89bb33c6aTest
    https://doi.org/10.1182/blood-2018-08-869453Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث